Want to see IDXX full AI Analyst Report?
IDXX Stock Chart & Stats
$589.25
$7.33(1.72%)
At close: 4:00 PM EST
$589.25
$7.33(1.72%)
Day’s Range― - ―
52-Week Range$506.91 - $769.98
Previous CloseN/A
Volume277.29K
Average Volume (3M)645.18K
Market Cap
$41.53B
Enterprise Value$43.98B
Total Cash (Recent Filing)$200.53M
Total Debt (Recent Filing)$1.11B
Price to Earnings (P/E)38.5
Beta0.82
Next Earnings
Aug 04, 2026EPS Estimate
3.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.67
Shares Outstanding78,882,996
10 Day Avg. Volume588,868
30 Day Avg. Volume645,179
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)33.75
Price to Sales (P/S)12.59
P/FCF Ratio51.44
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue9.89
Enterprise Value/Gross Profit15.94
Enterprise Value/Ebitda28.22
Forecast
1Y Price Target
$703.67Price Target Upside19.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)14.65
Revenue Forecast (FY)$4.71B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Software RevenueHigh-growth consumables and software recurring revenue tied to installed instruments provide durable, high-frequency cash flow. This attachment model creates predictable revenue, recurring margin support, and retention benefits that compound as installed base and utilization rise globally.
Strong Margins And Cash GenerationSustained high gross and operating margins alongside very strong free cash flow conversion underpin capital flexibility. Robust cash generation funds R&D, targeted capex, buybacks and M&A optionality while enhancing resilience to cyclical demand shocks over the medium term.
Instrument Adoption And Product RoadmapRapid placement of premium instruments expands the revenue base for future consumables and services and raises switching costs. A clear multi-product roadmap (inVue Dx menu expansion, Cancer DX, AI) supports longer-term penetration, upsell and cross-sell across clinics and labs.
Bears Say
Declining Clinical VisitsSustained weakness in clinic foot traffic, especially discretionary wellness visits, reduces test volumes per clinic and can cap consumable and service growth. If visit trends persist, utilization gains from installed instruments may slow, pressuring medium-term organic growth assumptions.
Rapid-assay Platform Migration HeadwindMigration of tests between platforms can materially alter product mix and revenue mix, creating recurring-revenue headwinds in affected assay lines. Such transitions require re-selling or instrument upgrades and can temporarily compress revenues and margins in specific consumable categories.
Executive Departure And ReorganizationLoss of a senior commercial and strategy executive during a strategic realignment raises execution risk for instrument rollouts and international expansion. Leadership turnover and organizational change can delay initiatives, alter go-to-market effectiveness, and increase short-to-medium term execution uncertainty.
Idexx Laboratories News
IDXX FAQ
What was Idexx Laboratories’s price range in the past 12 months?
Idexx Laboratories lowest stock price was $506.91 and its highest was $769.98 in the past 12 months.
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is $41.53B.
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is Aug 04, 2026 which is in 34 days.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on May 05, 2026. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is 3.96.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 78,882,996 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of $3.47 in its last earnings report, beating expectations of $3.41. Following the earnings report the stock price went down -0.028%.
Which hedge fund is a major shareholder of Idexx Laboratories?
Currently, no hedge funds are holding shares in IDXX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Idexx Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$703.67 (19.42% Upside)
$703.67 (19.42% Upside)
Blogger Sentiment
Bullish
IDXX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 27.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.86%
12-Months-Change
Fundamentals
Return on Equity
70.87%
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Idexx Laboratories
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
IDXX Company Deck
IDXX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong top-line growth, robust recurring revenue and instrument placement momentum, margin expansion, healthy EPS and cash generation, and continued adoption of new diagnostic innovations (inVue Dx, Cancer DX) and software solutions. These positives substantially outweigh the headwinds disclosed: modest declines in clinical visits (especially wellness), flat rapid assay revenues due to platform migration, some supply-chain impacts in Water, and a few discrete expense items (equity loss, prior litigation). Management raised full-year guidance and reaffirmed growth drivers while acknowledging macro and FX sensitivities. Overall, the tone is confident and constructive with execution-focused follow-through on innovation rollouts and international expansion.View all IDXX earnings summariesIDXX Revenue Breakdown
91.86% CAG
4.67% Water
3.06% LPD
0.41% Other
IDXX Stock 12 Month Forecast
Average Price Target
$703.67
▲(19.42% Upside)
Technical Analysis
Ownership Overview
0.23% Insiders
27.55% Mutual Funds
23.57% Other Institutional Investors
15.93% Public Companies and
Individual Investors